Premal Thaker, MD, MS, discusses important implications and takeaways of the phase 1/2 OVATION study of IMMN-1 in addition to chemotherapy for the treatment of newly diagnosed epithelial ovarian ...

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses ...

ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

Taxol is a widely used chemotherapy drug – it has been used to treat millions of ovarian, breast, and lung cancer patients. Today, it's mainly ...

The widely used chemotherapy drug paclitaxel, commonly known as Taxol, was first extracted from the Pacific yew tree in 1963.

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

Groundbreaking results from the Phase 3 POD1UM-303/InterAACT 2 trial have been published in The Lancet, showcasing the ...

Stanford University researchers report the discovery of eight previously unknown genes that, when expressed in tobacco leaves, reconstitute the Taxol precursor baccatin III at levels matching its ...

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz ® ), a humanized monoclonal antibody targeting programmed death ...